FDAFDA · Food and drugs·Recall number D-0100-2023
Rifampin Capsules USP, 300 mg, 30-count bottle; Rx Only, Manufactured for: Lupin Pharmaceuticals Baltimore, Maryland 21202, Manufactured by: Lupin Limited Aurangabad 431 210 India. NDC 68180-659-06
Published January 18, 2023 · Recall initiated: December 12, 2022
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study.
What to do
Voluntary: Firm initiated · Letter
Recall details
- Brand
- RIFAMPIN
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Distributor
- Distributed Nationwide in the USA
- Lot
- Lot # A200171, Exp 12/2023
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Sell products like this?
Recalert watches your whole catalog for recalls like this one, automatically.